Heska Corp. (HSKA) Coverage Initiated by Analysts at Benchmark Co.
A number of other analysts also recently issued reports on HSKA. B. Riley reiterated a neutral rating and issued a $53.00 price target on shares of Heska Corp. in a report on Wednesday, November 2nd. Zacks Investment Research downgraded shares of Heska Corp. from a buy rating to a hold rating in a report on Thursday, October 27th. Finally, Sidoti downgraded shares of Heska Corp. from a buy rating to a neutral rating and set a $71.00 price target on the stock. in a report on Monday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $66.88.
Shares of Heska Corp. (NASDAQ:HSKA) opened at 67.69 on Tuesday. The stock has a market capitalization of $466.93 million, a price-to-earnings ratio of 54.20 and a beta of 0.74. The stock’s 50 day moving average is $58.16 and its 200-day moving average is $48.46. Heska Corp. has a 12-month low of $26.25 and a 12-month high of $69.80.
Heska Corp. (NASDAQ:HSKA) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.20. The company had revenue of $33.40 million for the quarter, compared to the consensus estimate of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. The firm’s quarterly revenue was up 19.3% on a year-over-year basis. On average, analysts expect that Heska Corp. will post $1.32 earnings per share for the current year.
In other news, EVP Rod Lippincott sold 5,000 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $64.85, for a total value of $324,250.00. Following the sale, the executive vice president now directly owns 10,192 shares in the company, valued at approximately $660,951.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO John Mcmahon sold 1,999 shares of the business’s stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $65.64, for a total transaction of $131,214.36. Following the completion of the sale, the chief financial officer now owns 584 shares in the company, valued at $38,333.76. The disclosure for this sale can be found here. 15.30% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers increased its position in shares of Heska Corp. by 1.5% in the third quarter. Rhumbline Advisers now owns 6,056 shares of the company’s stock valued at $330,000 after buying an additional 90 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Heska Corp. by 0.8% in the third quarter. California State Teachers Retirement System now owns 12,890 shares of the company’s stock valued at $702,000 after buying an additional 100 shares during the last quarter. BlackRock Inc. increased its position in shares of Heska Corp. by 6.2% in the third quarter. BlackRock Inc. now owns 5,413 shares of the company’s stock valued at $295,000 after buying an additional 318 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its position in shares of Heska Corp. by 7.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,853 shares of the company’s stock valued at $180,000 after buying an additional 320 shares during the last quarter. Finally, Analytic Investors LLC increased its position in shares of Heska Corp. by 0.9% in the third quarter. Analytic Investors LLC now owns 37,289 shares of the company’s stock valued at $2,030,000 after buying an additional 334 shares during the last quarter. Institutional investors own 72.70% of the company’s stock.
Heska Corp. Company Profile
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Stock Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related stocks with our FREE daily email newsletter.